KINNATE BIOPHARMA INC's ticker is KNTE and the CUSIP is 49705R105. A total of 74 filers reported holding KINNATE BIOPHARMA INC in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $13,540,300 | -53.8% | 9,671,643 | 0.0% | 7.52% | -47.8% |
| Q2 2023 | $29,305,078 | -51.5% | 9,671,643 | 0.0% | 14.41% | -54.1% |
| Q1 2023 | $60,447,769 | +2.5% | 9,671,643 | 0.0% | 31.36% | +24.5% |
| Q4 2022 | $58,997,022 | -49.0% | 9,671,643 | 0.0% | 25.20% | -32.2% |
| Q3 2022 | $115,576,000 | -5.2% | 9,671,643 | 0.0% | 37.17% | +13.2% |
| Q2 2022 | $121,959,000 | +12.0% | 9,671,643 | 0.0% | 32.84% | +7.8% |
| Q1 2022 | $108,903,000 | -36.5% | 9,671,643 | 0.0% | 30.47% | -13.6% |
| Q4 2021 | $171,382,000 | -23.0% | 9,671,643 | 0.0% | 35.26% | +7.6% |
| Q3 2021 | $222,641,000 | -1.1% | 9,671,643 | 0.0% | 32.78% | +7.7% |
| Q2 2021 | $225,156,000 | -25.3% | 9,671,643 | 0.0% | 30.44% | -15.7% |
| Q1 2021 | $301,368,000 | -21.7% | 9,671,643 | 0.0% | 36.10% | -13.6% |
| Q4 2020 | $384,738,000 | – | 9,671,643 | – | 41.79% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 3,525,957 | $4,936,340 | 7.88% |
| Foresite Capital Management IV, LLC | 9,671,643 | $13,540,300 | 7.52% |
| Vida Ventures Advisors, LLC | 2,207,772 | $3,090,881 | 4.78% |
| Lynx1 Capital Management LP | 1,997,006 | $2,795,808 | 1.85% |
| Nextech Invest Ltd. | 2,329,480 | $3,261,272 | 0.99% |
| Orbimed Advisors | 8,009,729 | $11,213,621 | 0.24% |
| Novo Holdings A/S | 815,707 | $1,141,990 | 0.08% |
| DAFNA Capital Management LLC | 105,179 | $147,251 | 0.05% |
| GSA CAPITAL PARTNERS LLP | 374,291 | $524 | 0.04% |
| Rock Springs Capital Management LP | 405,811 | $568,135 | 0.02% |